CLINICAL SAFETY · UK The review Key hazards Safeguards Sources EVIDENCE BRIEFING · 29 OCTOBER 2026 The Fonagy Report, ADHD and the hazards of remote controlled-drug prescribing
CLINICAL SAFETY · UK
EVIDENCE BRIEFING · 29 OCTOBER 2026
The Fonagy Report, ADHD and the hazards of remote controlled-drug prescribing
A practical, evidence-informed look at the UK’s 2026 independent review—and what safe prescribing of stimulant medication requires when care is delivered at a distance.
Independent educational analysis · Not an official government publication · CD = controlled drug
01 / The evidence
What the Fonagy review actually says
Chaired by Professor Peter Fonagy, the Independent review into mental health conditions, ADHD and autism was published on 9 October 2026. It considers rising demand, diagnostic practice, access to care and the balance between recognising genuine need and avoiding inaccurate diagnosis.
FINDING 01
Diagnosis matters
Accurate ADHD diagnosis can unlock effective treatment and explain significant functional difficulties. Inaccurate diagnosis can lead to inappropriate treatment or missed alternative conditions.
FINDING 02
Needs-led support
The review recommends support according to needs and impairment, alongside access to diagnostic assessment—not withholding help until a diagnosis is obtained.
FINDING 03
System pressure
Rapidly increasing referrals and long waits expose gaps in assessment, follow-up and continuity of care.
Important distinction: The remote controlled-drug risk framework below is an analysis applying NICE and GMC standards to ADHD services. It should not be presented as a list of findings or recommendations directly made by the Fonagy review.
Sources: Fonagy review executive summary; full report.
02 / Patient safety
Six hazards of poorly governed remote stimulant prescribing
Many commonly prescribed ADHD stimulants, including methylphenidate and lisdexamfetamine, are Schedule 2 controlled drugs. Remote care can be appropriate, but it must deliver a sufficiently robust clinical assessment, reliable observations and follow-up.
RISK 01
Incomplete diagnosis
Short, questionnaire-led encounters may miss developmental history, functional impairment, coexisting disorders or alternative explanations for symptoms.
RISK 02
Missing physical baseline
Starting medication without reliable pulse, blood pressure, weight, cardiovascular history or indicated further assessment may expose avoidable harm.
RISK 03
Misuse and diversion
Weak identity checks, fragmented prescribing records or insufficient substance-use assessment can increase the risk of duplicate supply, misuse or diversion.
RISK 04
Inadequate titration
Remote dose changes without documented symptom benefit, adverse effects and appropriate physiological monitoring can miss emerging problems.
RISK 05
Fragmented accountability
Unclear responsibility between private services, specialist prescribers, GPs and pharmacies can interrupt monitoring, repeat prescriptions and escalation.
RISK 06
Commercial pressure
High-throughput or prescribing-led service models may create incentives that conflict with careful assessment and individualised treatment. This is a governance risk, not a claim about all private or online providers.
Clinical red flag: A remote prescription should not proceed merely because a patient has completed an online questionnaire or paid for an assessment. The prescriber must have adequate information, appropriate safeguards and a safe monitoring plan.
03 / Safer practice
What a defensible remote pathway looks like
StageEssential safeguardRelevant standardDiagnosisSpecialist assessment including developmental and psychiatric history, impairment across settings, mental state and corroborating information where appropriate.NICE NG87 §1.3Before prescribingConfirm continuing ADHD treatment need; assess mental health, substance misuse/diversion risk, medicines, cardiovascular history, pulse, blood pressure, height and weight.NICE NG87 §1.7.4Remote suitabilityDetermine whether remote consultation is clinically sufficient or an in-person examination is needed; verify identity and relevant records.GMC prescribing guidanceTitrationDocument symptoms, impairment and adverse effects at baseline and dose changes; review progress regularly with a specialist.NICE NG87 §§1.7.26–28Ongoing monitoringMeasure heart rate and blood pressure before and after dose changes and every six months; monitor weight and conduct at least annual specialist medication review.NICE NG87 §§1.8–1.10ContinuityClarify prescribing responsibility, information-sharing, escalation and any shared-care arrangements; do not assume a GP has accepted shared care.NICE NG87 §1.7.29; GMC
A routine ECG is not required for everyone before ADHD medication; NICE specifies when further cardiovascular assessment is indicated. The exact approach must be individualised.
Questions commissioners and clinical leaders should ask
Can the provider evidence a comprehensive diagnostic assessment?
Who verifies baseline observations and acts on abnormal results?
How are duplicate prescribing and diversion risks assessed?
Who reviews adverse effects and responds to urgent concerns?
What happens when shared care is declined or the patient moves?
Questions patients can ask
Who is my named prescribing clinician?
How will my blood pressure, pulse and weight be checked?
How can I report side effects or deterioration?
Will my GP receive the relevant information, with my consent?
Who continues treatment if remote follow-up is not suitable?
Bottom line: The relevant safety test is not simply remote versus face-to-face. It is whether the pathway meets the same clinical, prescribing and monitoring obligations, with an in-person assessment whenever clinically necessary.
04 / References
Primary sources and further reading
Department of Health and Social Care — Independent review into mental health conditions, ADHD and autism: final report(published 9 October 2026; updated 21 October 2026).
NICE NG87 — Attention deficit hyperactivity disorder: diagnosis and management.
GMC — Controlled drugs and other medicines where additional safeguards are needed.
This page is an independent educational commentary, not a systematic review, clinical protocol or substitute for current law, local policy or individual clinical judgement. It does not allege misconduct by any particular service. Last reviewed 29 October 2026.
ADHD care should be accessible, evidence-based and safe.
Comments